Skip Navigation



European Heart Journal Advance Access published online on May 25, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi339
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
26/21/2294    most recent
ehi339v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Speidl, W. S.
Right arrow Articles by Schillinger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Speidl, W. S.
Right arrow Articles by Schillinger, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2005; All rights reserved
Received February 10, 2005
Revised April 9, 2005
Accepted April 28, 2005

Clinical research

Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis

Walter S. Speidl 1, Markus Exner 2, Jasmin Amighi 3, Stefan P. Kastl 1, Gerlinde Zorn 1, Gerald Maurer 1, Oswald Wagner 2, Kurt Huber 4, Erich Minar 3, Johann Wojta 1, and Martin Schillinger 3*

1 Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; Ludwig Boltzmann Foundation for Cardiovascular Research, Vienna, Austria
2 Department of Laboratory Medicine, Medical University of Vienna, Austria
3 Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
4 Third Medical Department, Wilhelminenhospital, Vienna, Austria

* To whom correspondence should be addressed.
Martin Schillinger, E-mail: martin.schillinger{at}meduniwien.ac.at


  Abstract

Aims Complement activation occurs in atherosclerotic lesions, and particularly complement component C5a exerts potent chemotactic and proinflammatory effects. However, it is yet unknown, whether plasma levels of C5a may predict cardiovascular risk. The aim of this study was to examine whether plasma levels of the complement component C5a may predict cardiovascular risk in patients with advanced atherosclerosis.

Methods and results We studied 173 patients with symptomatic peripheral artery disease (median age 72, 82 male). Cardiovascular risk profile, levels of the complement factor C5a, and other non-specific inflammatory parameters [high sensitivity C-reactive protein, serum amyloid A (SAA), and fibrinogen] were obtained at baseline, and patients were followed for median 22 months [interquartile range (IQR) 13-27] for the occurrence of major adverse cardiovascular events (MACE: myocardial infarction, percutaneous coronary interventions, coronary artery bypass graft, carotid revascularization, stroke, and death). We observed 65 MACE in 49 patients (28%). Cumulative event rates (95% confidence interval (CI)) within quartiles of C5a at 24 months were 16 (5-27), 26 (13-39), 36 (21-51), and 37% (23-51), respectively (P = 0.0077). Adjusted hazard ratios for the occurrence of a first MACE according to increasing quartiles of C5a were 1.81, 2.23, and 2.66, respectively, as compared to the lowest quartile (P = 0.038), irrespective of the level of other inflammatory parameters.

Conclusion Complement activation, indicated by the elevation of C5a, seems to be associated with increased cardiovascular risk in patients with advanced atherosclerosis. Clinically, determination of C5a may add to the predictive value of other non-specific inflammatory parameters.

Keywords: Atherosclerosis; Complications; Complement factor; Inflammation.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. P. Kastl, W. S. Speidl, C. Kaun, K. M. Katsaros, G. Rega, T. Afonyushkin, V. N. Bochkov, P. Valent, A. Assadian, G. W. Hagmueller, et al.
In Human Macrophages the Complement Component C5a Induces the Expression of Oncostatin M via AP-1 Activation
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 498 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
F. Verdeguer, C. Castro, M. Kubicek, D. Pla, M. Vila-Caballer, A. Vinue, F. Civeira, M. Pocovi, J. J. Calvete, and V. Andres
Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation
Cardiovasc Res, November 1, 2007; 76(2): 340 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
G. M. Howard-Alpe, J. W. Sear, and P. Foex
Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers
Br. J. Anaesth., December 1, 2006; 97(6): 758 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. T. Keller, S. I. van Leuven, M. C. Meuwese, N. J. Wareham, R. Luben, E. S. Stroes, C. E. Hack, M. Levi, K.-T. Khaw, and S. M. Boekholdt
Serum Levels of Mannose-Binding Lectin and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2345 - 2350.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.